|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Commercial and Pipeline Insight: Hepatitis B
Critical evaluation and ten year forecast of hepatis B market, including antivirals and immunomodulators. Assessment of prophylactic and therapeutic vaccines and their commercial potential.
Commercial Insight: Pain Market Overview
Analysis of key market trends and growth areas in the current and future prescription pain drug market sector with quantitative analysis and segmentation of the market from 200407 and forecasts to 2017 at a regional and class level.
Commercial Insight: CNS Market Overview
Analysis of the current and future central nervous system (CNS) pharmaceutical market across the seven major markets (7MM), defined as comprising three key sectors: neurology, pain and psychiatry.
Pipeline/Commercial Insight: Supportive Care in Oncology
Analysis of the current and future potential of the oncology supportive care market. Includes in-depth profiles of the late-phase pipeline, strategic recommendations and forecasts to 2016 for key marketed products across the seven major markets.
Commercial Insight: HIV - The battle for market...
Assessment and forecast for marketed and late-stage development antiretrovirals in the 7MM, including a snapshot of ROW snapshot and a case study on the Canadian market, which surpasses Japan’s in size for this indication.
Commercial Insight: Antidiabetics 2007
In-depth analysis of the current status and future potential of the marketed antidiabetic drug classes. Drug classes covered include sulfonylureas, biguanides, insulin, TZDs, AGIs, prandial glucose regulators and Incretin Mimetics.
Commercial Insight: Antidyslipidemics 2007
In-depth review of the current antidyslipidemics market. Explores the opportunities and threats of the seven major markets, key events that are likely to impact the performance of the antidyslipidemics, and provides sales forecasts to 2016.
Commercial Insight: Autoimmune Overview
The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for ’early’ dis
Commercial Insight: Cardiovascular market overview
Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of produ
Commercial Insight: Migraine - Opportunities will exist
Detailed analysis of the migraine market, including an assessment of country-specific events and company strategies. Includes an indication specific ten-year forecast for marketed products across the seven major markets (7MM).
Commercial Insight: Infectious Diseases Overview
A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to hig
Commercial Insight: Asthma & COPD - Combination products...
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major mark
Commercial Insight: Top 20 Therapy Cancer Brands
Overview and analysis of the 20 leading cancer therapy brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales and an in-depth review of market dynamics.
Commercial Insight: Antithrombotics - Market expands...
Analysis of the competitive landscape for novel agents, across seven major markets. This includes the threats to currently marketed drugs, in terms of loss of market exclusivity and a predictive evaluation of loss of market share to novel agents.
Commercial and Pipeline Insight: Infertility
This report provides full analysis of the current and future infertility drug market, with indication-specific forecasts to 2016 for marketed and key pipeline drugs. Analysis is supplemented with opinion leader comment
Commercial Insight: Top 20 Cancer Therapy Brands
Overview and analysis of the 20 leading cancer therapy brands in each of the seven major markets based on 2006 sales. Includes forecasts to 2016 in light of key events set to influence product sales and an in-depth review of market dynamics.
Commercial Insight: Antihypertensives
Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies n
Commercial Insight: Generic Cancer Market
Over the next 10 years a significant number of key oncology products, some with blockbuster status, will lose patent protection, thus exposing billions of dollars to generic erosion. While obviously a major threat to the key pharmaceutical players and
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes
The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufactu
Commercial Insight: Asthma and COPD - Get SMART
There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several la
Commercial Insight: Antidiabetics - Billion Dollar Drugs
The diabetes epidemic has contributed to the expansion of the antidiabetics market in the past few years, and with prevalence increasing, this trend is set to continue. However, the highest selling drug classes in the market (sulfonylureas and biguani
Commercial Insight: HIV - Simplicity and Survival
Despite accounting for only 1% of global pharmaceutical sales, HIV antiretrovirals have experienced rapid growth between 2000-2004, accounting for $6.6 billion in global sales. Enthusiasm for new once daily FDCs and PIs such as Reyataz has rendered th
Commercial Insight: Antihormonal Therapies Aromatase Inhibitors
The antihormonal cancer therapy market is characterized by a mature nature and a relatively high level of saturation. Despite this, growth will continue slowly at a CAGR of 0.9% during 2004-14, with those areas in decline offset by clear potential fro
$15 200.00
|
